NZ714079A - Purification process for monoclonal antibodies - Google Patents

Purification process for monoclonal antibodies

Info

Publication number
NZ714079A
NZ714079A NZ714079A NZ71407914A NZ714079A NZ 714079 A NZ714079 A NZ 714079A NZ 714079 A NZ714079 A NZ 714079A NZ 71407914 A NZ71407914 A NZ 71407914A NZ 714079 A NZ714079 A NZ 714079A
Authority
NZ
New Zealand
Prior art keywords
monoclonal antibodies
purification process
monoclonal antibody
purification
provides
Prior art date
Application number
NZ714079A
Other languages
English (en)
Inventor
Sanjeev Kumar Mendiratta
Sanjay Bandyopadhyay
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ714079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of NZ714079A publication Critical patent/NZ714079A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
NZ714079A 2013-06-25 2014-06-25 Purification process for monoclonal antibodies NZ714079A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (enExample) 2013-06-25 2014-06-25
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies

Publications (1)

Publication Number Publication Date
NZ714079A true NZ714079A (en) 2017-05-26

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies

Country Status (19)

Country Link
US (1) US9708365B2 (enExample)
EP (1) EP3013849B1 (enExample)
JP (1) JP6039828B2 (enExample)
KR (1) KR101683415B1 (enExample)
CN (1) CN105263947A (enExample)
AR (1) AR096713A1 (enExample)
AU (1) AU2014300486B2 (enExample)
BR (1) BR112015031196A2 (enExample)
CA (1) CA2911874A1 (enExample)
EA (1) EA201592192A1 (enExample)
HK (1) HK1217344A1 (enExample)
IL (1) IL242649A (enExample)
IN (1) IN2013MU02145A (enExample)
MX (1) MX350610B (enExample)
NZ (1) NZ714079A (enExample)
SG (1) SG11201509502XA (enExample)
TW (1) TWI596107B (enExample)
WO (1) WO2014207763A1 (enExample)
ZA (1) ZA201508258B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH088818Y2 (ja) 1989-12-21 1996-03-13 株式会社イナックス タイル用捺印装置
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016118707A1 (en) * 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
KR102490956B1 (ko) * 2015-03-13 2023-01-19 브리스톨-마이어스 스큅 컴퍼니 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도
PL3337817T3 (pl) 2015-08-21 2022-01-17 F. Hoffmann-La Roche Ag Sposób zmniejszania zawartości białek komórek gospodarza w chromatografii powinowactwa
PL3337812T3 (pl) * 2015-08-21 2021-10-11 F. Hoffmann-La Roche Ag Sposób zmniejszenia zawartości białek komórki gospodarza w chromatografii powinowactwa
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
ES3032778T3 (en) 2016-10-25 2025-07-24 Regeneron Pharma Methods for chromatography data analysis
KR102617873B1 (ko) 2016-10-28 2023-12-22 머크 샤프 앤드 돔 엘엘씨 티로신 황산화 항체 변이체의 제거를 위한 정제 프로세스, 정제된 조성물
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
TWI679052B (zh) * 2017-05-16 2019-12-11 南韓商Ｃｊ醫藥健康股份有限公司 使用親和力層析術純化抗體或其抗體片段的方法
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
MY203415A (en) 2017-09-19 2024-06-27 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020016417A1 (en) * 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
TW202045527A (zh) * 2019-01-23 2020-12-16 日商第一三共股份有限公司 包含使用活性碳材料之步驟之抗體純化方法
WO2021099536A1 (en) 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
WO2021139720A1 (zh) * 2020-01-08 2021-07-15 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
US12454567B2 (en) 2021-07-27 2025-10-28 Ariel Scientific Innovations Ltd. Large scale purification of antibodies
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides
CN118725127B (zh) * 2024-07-11 2025-11-28 信立泰(苏州)药业有限公司 一种抗pcsk9单克隆抗体的分离纯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
SI1308456T1 (sl) 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
DE69919701T2 (de) * 1998-06-01 2005-09-15 Genentech, Inc., South San Francisco Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
JPWO2004087761A1 (ja) 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
KR101482791B1 (ko) * 2005-03-11 2015-01-21 와이어쓰 엘엘씨 약한 분배성 크로마토그래피법
EA201100177A1 (ru) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
CL2007002615A1 (es) 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
EP2326658A4 (en) 2008-09-12 2013-04-10 Ge Healthcare Bio Sciences Ab REMOVAL OF REINFORCED PROTEIN AGGREGATES WITH MULTIMODAL ANION DERIVATIVES IN THE PRESENCE OF TWITTERS WITHOUT PROTEINS
KR20110091678A (ko) * 2008-10-20 2011-08-12 아보트 러보러터리즈 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제
PL3037104T3 (pl) 2009-10-20 2020-11-16 Abbvie Inc. Izolacja i oczyszczanie przeciwciał anty-il-13 z zastosowaniem chromatografii powinowactwa z białkiem a
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
ES2492681T3 (es) 2010-01-22 2014-09-10 Boehringer Ingelheim International Gmbh Método cromatográfico para purificar proteínas que contienen FC
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
JP2013544524A (ja) * 2010-12-06 2013-12-19 ターポン バイオシステムズ，インコーポレイテッド 生物学的生成物の連続プロセス法
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
EP3395423B1 (en) * 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand
CN105324393A (zh) * 2013-05-13 2016-02-10 米迪缪尼有限公司 具有最小单体分离的重组多克隆抗体多聚体的分离
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales

Also Published As

Publication number Publication date
AR096713A1 (es) 2016-01-27
CA2911874A1 (en) 2014-12-31
TW201512217A (zh) 2015-04-01
US20160115195A1 (en) 2016-04-28
BR112015031196A2 (pt) 2017-07-25
EA201592192A1 (ru) 2016-07-29
SG11201509502XA (en) 2015-12-30
IL242649A (en) 2016-03-31
EP3013849A1 (en) 2016-05-04
ZA201508258B (en) 2017-03-29
MX2015016586A (es) 2016-03-16
IN2013MU02145A (enExample) 2015-06-05
HK1217344A1 (zh) 2017-01-06
JP2016525500A (ja) 2016-08-25
US9708365B2 (en) 2017-07-18
KR20160003311A (ko) 2016-01-08
KR101683415B1 (ko) 2016-12-06
JP6039828B2 (ja) 2016-12-07
WO2014207763A1 (en) 2014-12-31
MX350610B (es) 2017-09-11
AU2014300486B2 (en) 2016-06-30
TWI596107B (zh) 2017-08-21
AU2014300486A1 (en) 2015-11-26
CN105263947A (zh) 2016-01-20
EP3013849B1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
NZ714079A (en) Purification process for monoclonal antibodies
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MX2023008870A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
GB201911685D0 (en) Process for purifying monoclonal antibodies
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
TR201818966T4 (tr) İyon değişim kromatografisi girdi optimizasyonunun açıklaması.
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
MY197993A (en) Method for protein purification
NZ724772A (en) Antibodies against hpa-1a
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
WO2018207184A3 (en) Methods of purifying antibodies
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
EP4239329A3 (en) Method and apparatus
JOP20210100A1 (ar) جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
EP4524563A3 (en) Flow based assays for therapeutics

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed